NASDAQ: ORGS
Morningstar‘s Stock Analysis ORGS
Valuation
Currency in —
Is it the right time to buy or sell?
Is it the right time to buy or sell?
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
About Quantitative Ratings
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Unlock Our Full Analysis With Morningstar Investor
Company Profile ORGS
Business Description
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company’s business includes two reporting segments: Morgenesis and Therapies.
Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.
Orgenesis Inc
XNAS: ORGS
| Renovaro Biosciences Inc
XNAS: RENB
| Forma Therapeutics Holdings Inc Ordinary Shares
XNAS: FMTX
| Molecular Templates Inc
XNAS: MTEM
| |
Price
| 0.63 | 3.90 | — | 6.70 |
Currency
| USD | USD | — | USD |
Change
| +$0.04 (6.38%) | +$0.05 (1.30%) | — | +$0.15 (2.28%) |
Market Cap
| 19.19 Mil | 248.42 Mil | — | 36.00 Mil |
Industry
| Biotechnology | Biotechnology | Biotechnology | Biotechnology |
Sector
|
Healthcare
|
Healthcare
|
Healthcare
|
Healthcare
|
* Trading data in this section is delayed by at least 15 minutes.
FAQs for Orgenesis Inc Stock
No. ORGS does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
ORGS’s market cap is 19.19 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the
largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
ORGS’s stock style is Small Value.
Style is an investment factor that has a meaningful impact on investment risk and returns.
Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
ORGS’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare ORGS’s historical performance against its industry peers and the overall market.